Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trivalent-Tasmania influenza vaccine
- Development stage
- Phase 1
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent-Tasmania influenza vaccine is an influenza vaccine formulation developed by Sanofi Pasteur. It is administered as a suspension for intramuscular injection. The vaccine is designed to evaluate the safety and immunogenicity of an influenza vaccine formulation composed of WHO-recommended virus strains, including an additional H3 strain, to induce an immune response against influenza. It is currently in Phase I clinical trials for influenza prevention in healthy adults.
- Other names
- Trivalent-Tasmania influenza vaccine
02
Targets
Flu (Influenza surface proteins)
Beyond the preview
Go deeper on Trivalent-Tasmania influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trivalent-Tasmania influenza vaccine.